Trevi Therapeutics, Inc.

NasdaqGM:TRVI Stock Report

Market Cap: US$1.4b

Trevi Therapeutics Valuation

Is TRVI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of TRVI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate TRVI's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate TRVI's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TRVI?

Key metric: As TRVI is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for TRVI. This is calculated by dividing TRVI's market cap by their current book value.
What is TRVI's PB Ratio?
PB Ratio7.5x
BookUS$189.79m
Market CapUS$1.36b

Price to Book Ratio vs Peers

How does TRVI's PB Ratio compare to its peers?

The above table shows the PB ratio for TRVI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.7x
ATAI AtaiBeckley
9x35.39%US$1.4b
AMPH Amphastar Pharmaceuticals
1.6x4.16%US$1.3b
COLL Collegium Pharmaceutical
5.2x26.28%US$1.4b
RAPP Rapport Therapeutics
2.8x-14.49%US$1.4b
TRVI Trevi Therapeutics
7.5x45.38%US$1.4b

Price-To-Book vs Peers: TRVI is expensive based on its Price-To-Book Ratio (7.5x) compared to the peer average (4.7x).

Historical Price to Book Ratio

Historical Price to Book Ratio compares a stock's price to the book value of it's equity over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Book Ratio vs Industry

How does TRVI's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

26 CompaniesPrice / BookEstimated GrowthMarket Cap
PLRX Pliant Therapeutics
0.4x0.21%US$76.20m
HYPD Hyperion DeFi
0.4x97.80%US$27.63m
CTXR Citius Pharmaceuticals
0.2x43.71%US$15.86m
KPRX Kiora Pharmaceuticals
0.3x61.14%US$7.26m
TRVI 7.5xIndustry Avg. 2.3xNo. of Companies26PB01.63.24.86.48+
26 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: TRVI is expensive based on its Price-To-Book Ratio (7.5x) compared to the US Pharmaceuticals industry average (2.3x).

Price to Book Ratio vs Fair Ratio

What is TRVI's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TRVI PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio7.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate TRVI's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TRVI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$11.10
US$21.55
+94.10%
15.12%US$27.00US$16.00n/a11
Feb ’27US$10.47
US$21.55
+105.78%
15.12%US$27.00US$16.00n/a11
Jan ’27US$12.52
US$21.09
+68.46%
17.21%US$27.00US$16.00n/a11
Dec ’26US$13.30
US$20.82
+56.53%
18.97%US$27.00US$15.00n/a11
Nov ’26US$11.66
US$20.36
+74.65%
21.28%US$27.00US$13.00n/a11
Oct ’26US$9.40
US$20.36
+116.63%
21.28%US$27.00US$13.00n/a11
Sep ’26US$7.26
US$20.36
+180.68%
21.28%US$27.00US$13.00n/a11
Aug ’26US$7.33
US$21.60
+194.68%
21.03%US$29.00US$13.00n/a10
Jul ’26US$5.70
US$21.60
+278.95%
21.03%US$29.00US$13.00n/a10
Jun ’26US$6.51
US$20.67
+217.46%
24.25%US$29.00US$11.00n/a9
May ’26US$6.90
US$19.83
+187.44%
28.92%US$29.00US$11.00n/a9
Apr ’26US$6.01
US$19.83
+230.01%
28.92%US$29.00US$11.00n/a9
Mar ’26US$4.52
US$10.72
+137.22%
37.64%US$21.00US$7.00n/a9
Feb ’26US$3.94
US$9.94
+152.40%
40.81%US$21.00US$7.00US$10.479
Jan ’26US$4.12
US$9.81
+138.17%
43.68%US$21.00US$7.00US$12.528
Dec ’25US$2.88
US$9.11
+216.36%
47.55%US$21.00US$6.00US$13.309
Nov ’25US$3.01
US$9.11
+202.69%
47.55%US$21.00US$6.00US$11.669
Oct ’25US$3.11
US$9.11
+192.96%
47.55%US$21.00US$6.00US$9.409
Sep ’25US$3.16
US$9.00
+184.81%
48.86%US$21.00US$6.00US$7.269
Aug ’25US$3.10
US$7.40
+138.71%
16.22%US$9.00US$6.00US$7.335
Jul ’25US$2.89
US$7.40
+156.06%
16.22%US$9.00US$6.00US$5.705
Jun ’25US$2.57
US$7.40
+187.94%
16.22%US$9.00US$6.00US$6.515
May ’25US$2.86
US$7.40
+158.74%
16.22%US$9.00US$6.00US$6.905
Apr ’25US$3.36
US$7.40
+120.24%
16.22%US$9.00US$6.00US$6.015
Mar ’25US$2.93
US$7.40
+152.56%
16.22%US$9.00US$6.00US$4.525
Feb ’25US$1.39
US$7.40
+432.37%
16.22%US$9.00US$6.00US$3.945
US$21.55
Fair Value
48.5% undervalued intrinsic discount
11
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/23 13:46
End of Day Share Price 2026/02/23 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Trevi Therapeutics, Inc. is covered by 16 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBMO Capital Markets Equity Research
Mayank MamtaniB. Riley Securities, Inc.
William WoodB. Riley Securities, Inc.